We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Valeant will pony up at least $54 million to settle Justice Department allegations that one of its subsidiaries paid kickbacks to convince physicians to prescribe more of its products. Read More
Colombia’s Ministry of Health and Social Protection announced its plans to unilaterally cut the price of Novartis’ myeloid leukemia treatment Gleevec after negotiations with the Swiss drugmaker fell through the cracks. Read More
Biopharmaceutical firm Biocad has filed suit against Roche and its Genentech subsidiary over their alleged use of predatory pricing practices in Russia intended to decimate the sales of the Russian drugmaker’s biosimilars. Read More
Citing the nation’s opioid epidemic, the two top members of the Senate Special Committee on Aging have written to five different drugmakers inquiring about their efforts to improve access to opioid rescue drug naloxone. Read More
A district court judge has spared Gilead from paying a hefty sum in damages to Merck over a HCV patent dispute, overturning a March San Jose federal jury ruling. Read More
While retail prices for cancer drugs may be the highest in the U.S., these medicines appear to be less affordable in poorer countries such as India and China despite their lower prices, according to a study. Read More
Vermont Gov. Peter Shumlin signed into law Friday a transparency bill that would require certain drugmakers to justify their price increases for specific products. Read More